Year: 2013
Type: review
Abstract: Insect-derived baculoviruses have emerged as versatile and safe workhorses of biotechnology. Baculovirus expression vectors (BEVs) have been applied widely for crop and forest protection, as well as safe tools for recombinant protein production in insect cells. However, BEVs ability to efficiently transduce noninsect cells is still relatively poorly recognized despite the fact that efficient baculovirus-mediated in vitro and ex vivo gene delivery into dormant and dividing vertebrate cells of diverse origin has been described convincingly by many authors. Preliminary proof of therapeutic potential has also been established in preclinical studies. This review summarizes the advantages and current status of baculovirus-mediated gene delivery. Stem cell transduction, preclinical animal studies, tissue engineering, vaccination, cancer gene therapy, viral vector production, and drug discovery are covered.
Source: Molecular Therapy
DOI: 10.1038/mt.2012.286
Institutions: University of Eastern Finland, National Tsing Hua University, GlaxoSmithKline (United States), National Institutes of Health, National Heart, Lung, and Blood Institute, Research Institute for Microbial Diseases, The University of Osaka, The University of Osaka, National University of Singapore, Institute of Bioengineering and Nanotechnology, Kuopio University Hospital
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $4,500
OpenAlex ID: W2065616233
